💡 Have you heard of Dan Vahdat? He’s the visionary Founder of Huma, a digital health pioneer transforming patient care through remote monitoring and disease management platforms. After pausing his PhD, Dan built Huma, which has since supported over 3,000 hospitals and clinics, serving 27 million patients worldwide. Now, nearing unicorn status and profitability, Huma is leading the way in proactive and predictive healthcare!
Under Dan’s leadership, Huma became the first company to receive regulatory clearance in Europe and the US for its configurable disease management platform. He aims to make Huma the “Shopify” of digital health, providing the infrastructure for other companies to build and scale their digital health programs more efficiently and affordably. This approach could revolutionize how digital health solutions are delivered, making personalized care accessible to millions of more patients!
🎙️ In Episode 30, Dan discusses Huma’s journey, their strategy for success, and his vision for the future of healthcare! Tune in to explore how Huma is shaping the next generation of patient care!
💤 Revolutionizing sleep tech: that is the challenge that Soumya Dash and his team at Sleepiz undertook! A bold claim but certainly close to reality, considering their innovative approach to clinical sleep monitoring!
Sleepiz’s device is a small box that you put on your bedside table and which uses radar technology to analyze sleep patterns. It allows you to measure your sleep quality and identify disorders like sleep apnea without the need to wear uncomfortable equipment like traditional methods require. The result is an easier way to monitor sleep, fully remotely and with clinical-grade quality, facilitating the diagnosis and management of sleep-related conditions.
🎙️ In Episode 31, we dive into the technology behind Sleepiz, its benefits, and the potential of their technology beyond sleep monitoring! Discover how this is changing the field of sleep tech and get insights into the company’s journey and vision!
Are clinical wearables getting an update?
⌚ LIOM (formerly named “Spiden”) is on the verge of redefining continuous glucose monitoring with the future release of its proprietary wearable device! Combining the measurement of multiple vitals, sleep, activity, and their unique non-invasive continuous glucose measurement method, LIOM aims to become the most advanced wearable providing a multitude of clinical grade signals, continuously and non-invasively.
We had the chance to talk to Leo Grünstein, LIOM’s Founder and CEO, on the podcast in 2023 (you can listen to the episode here) and we wanted to share this important update on their journey toward commercialization!
You can follow their journey on Instagram @liomhealth and on their website, including daily tips on all things health and longevity!
The future of preventive healthcare and imaging?
🔍 Full-body MRI scans are gaining popularity as a tool for early detection of potential health issues, offering a comprehensive view of the body’s internal structures. These scans can identify abnormalities that might not yet be causing symptoms, potentially catching serious conditions like cancer or cardiovascular diseases early.
While the technology is impressive, the approach has been polarizing the medical community, with medical professionals highlighting their heavy price tag and high rate of false positive findings, versus its supporters seeing such scans as an efficient way to catch dangerous conditions early.
At this stage, there is no evidence that full-body MRI screening is cost-effective or prolongs life in asymptomatic individuals.
As companies like Prenuvo and Ezra are showing very rapid growth in the US with plans to expand to additional geographies, they might be able to run longitudinal studies on large patient cohorts to demonstrate the benefits of this preventive approach at a health system level.
Only time will tell.
Find out more about the topic in this detailed article from The MD Anderson Cancer Center.
🧫 A new era of targeted therapy: monoclonal antibodies
Monoclonal antibodies are a cornerstone of modern medicine, providing targeted treatment for diseases like cancer. But the journey started back in 1975 when César Milstein and Georges Köhler discovered how to create these lab-made molecules for the first time.
Before this breakthrough, treating diseases often meant affecting healthy tissues with hardcore chemical treatments, leading to many side effects. Monoclonal antibodies changed that by allowing doctors to target only diseased cells, making treatments more effective and less harmful. This innovation opened the door to personalized medicine and has since saved countless lives.
Left: micrograph of the first hybridoma obtained, recognizable by the halo of lysis produced by the anti-erythrocyte monoclonal antibody. Right: César Milstein and Georges Köhler on the day they received the Nobel Prize in Physiology and/or Medicine in 1984.
#support - As you might know, the Impulse Podcast and all the content we produce around it is the fruit of a voluntary passion project, and we are always keen to receive your support to grow the show and make sure we can sustain our activities in the long term! That’s why we would encourage you to subscribe to the podcast, leave a 5-star review on Spotify and Apple Podcasts, and share it with your surroundings or colleagues who might be interested in the subjects we cover! 🙏
#conference - I will be speaking at MedTech Malta on November 7! Dylan Attard and his team at MedTech World invited me to moderate the panel “Young Visionaries: Under-30 CEOs Shaping Tomorrow” where we will talk about medtech entrepreneurship with three emerging leaders! To secure your ticket, head over to med-tech.world/get-tickets and use the code MTWMaltaMathieuChaffard150OFF to get 150€ off on any Premium or Platinum tickets! See you there! ✌️
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.